| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lyme Disease | 31 | 2021 | 123 | 4.780 |
Why?
|
| Borrelia burgdorferi | 15 | 2021 | 93 | 2.380 |
Why?
|
| Antibodies, Monoclonal | 14 | 2025 | 875 | 2.060 |
Why?
|
| Borrelia burgdorferi Group | 18 | 2015 | 30 | 1.490 |
Why?
|
| Neutrophils | 44 | 1998 | 395 | 1.460 |
Why?
|
| Lipoproteins | 6 | 2021 | 85 | 1.270 |
Why?
|
| Bacterial Vaccines | 5 | 2021 | 79 | 1.210 |
Why?
|
| Bacterial Outer Membrane Proteins | 5 | 2021 | 127 | 1.190 |
Why?
|
| Enterotoxigenic Escherichia coli | 7 | 2023 | 22 | 1.120 |
Why?
|
| Antibodies, Neutralizing | 4 | 2025 | 217 | 1.080 |
Why?
|
| Anti-Bacterial Agents | 11 | 2013 | 801 | 1.070 |
Why?
|
| Antibodies, Bacterial | 12 | 2023 | 181 | 0.990 |
Why?
|
| Diphtheria Toxin | 1 | 2025 | 6 | 0.930 |
Why?
|
| Diphtheria Antitoxin | 1 | 2025 | 4 | 0.930 |
Why?
|
| Matrix Metalloproteinase 9 | 7 | 2007 | 65 | 0.900 |
Why?
|
| Antigens, Surface | 5 | 2021 | 199 | 0.860 |
Why?
|
| Disease Transmission, Infectious | 2 | 2016 | 20 | 0.730 |
Why?
|
| Immunoglobulin A, Secretory | 6 | 2023 | 22 | 0.720 |
Why?
|
| Escherichia coli Infections | 6 | 2023 | 90 | 0.700 |
Why?
|
| Plasminogen | 5 | 1997 | 8 | 0.610 |
Why?
|
| Immunoglobulin A | 5 | 2022 | 102 | 0.560 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 261 | 0.530 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 250 | 0.500 |
Why?
|
| Lysosomes | 13 | 1988 | 173 | 0.490 |
Why?
|
| Skin | 3 | 2010 | 422 | 0.490 |
Why?
|
| Ceftriaxone | 4 | 2003 | 20 | 0.490 |
Why?
|
| Humans | 113 | 2025 | 65140 | 0.480 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2016 | 16 | 0.480 |
Why?
|
| Escherichia coli Vaccines | 3 | 2021 | 11 | 0.460 |
Why?
|
| Immunologic Factors | 1 | 2016 | 110 | 0.450 |
Why?
|
| Monocytes | 3 | 2007 | 361 | 0.440 |
Why?
|
| Erythema Chronicum Migrans | 2 | 2005 | 9 | 0.430 |
Why?
|
| Up-Regulation | 2 | 2007 | 374 | 0.420 |
Why?
|
| Calcium | 8 | 1988 | 584 | 0.420 |
Why?
|
| Doxycycline | 4 | 2003 | 47 | 0.400 |
Why?
|
| Serologic Tests | 2 | 2012 | 34 | 0.400 |
Why?
|
| Communicable Diseases | 3 | 2007 | 86 | 0.380 |
Why?
|
| Fibroblasts | 3 | 2007 | 422 | 0.380 |
Why?
|
| Immunoglobulin G | 11 | 2022 | 465 | 0.380 |
Why?
|
| Disasters | 2 | 2005 | 28 | 0.370 |
Why?
|
| Urokinase-Type Plasminogen Activator | 3 | 1996 | 12 | 0.360 |
Why?
|
| Single-Domain Antibodies | 2 | 2022 | 21 | 0.350 |
Why?
|
| Diarrhea | 3 | 2021 | 73 | 0.350 |
Why?
|
| Animals | 34 | 2022 | 21345 | 0.350 |
Why?
|
| Immunization, Passive | 4 | 2023 | 96 | 0.340 |
Why?
|
| Clindamycin | 7 | 1996 | 13 | 0.340 |
Why?
|
| Bacillus anthracis | 1 | 2010 | 7 | 0.330 |
Why?
|
| Double-Blind Method | 7 | 2025 | 739 | 0.320 |
Why?
|
| Intestinal Diseases | 1 | 2010 | 37 | 0.310 |
Why?
|
| Mice, Inbred C3H | 3 | 2019 | 173 | 0.300 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2007 | 144 | 0.280 |
Why?
|
| Chronic Disease | 8 | 2013 | 742 | 0.270 |
Why?
|
| Epitopes | 7 | 2022 | 291 | 0.270 |
Why?
|
| Disease Vectors | 1 | 2007 | 7 | 0.260 |
Why?
|
| Disease Reservoirs | 1 | 2007 | 10 | 0.260 |
Why?
|
| Macrophages | 7 | 1991 | 1038 | 0.260 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2007 | 14 | 0.260 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 61 | 0.260 |
Why?
|
| Specialization | 2 | 1999 | 82 | 0.250 |
Why?
|
| Communicable Disease Control | 1 | 2007 | 40 | 0.250 |
Why?
|
| Drug Therapy, Combination | 4 | 2003 | 463 | 0.250 |
Why?
|
| HLA-DR Antigens | 2 | 2005 | 26 | 0.240 |
Why?
|
| Mice | 17 | 2022 | 11119 | 0.240 |
Why?
|
| Superoxides | 11 | 1998 | 73 | 0.230 |
Why?
|
| Diphtheria | 1 | 2025 | 5 | 0.230 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2006 | 23 | 0.230 |
Why?
|
| Escherichia coli | 6 | 2013 | 714 | 0.230 |
Why?
|
| Healthy Volunteers | 1 | 2025 | 72 | 0.230 |
Why?
|
| Disease Outbreaks | 2 | 2016 | 110 | 0.230 |
Why?
|
| Neutralization Tests | 1 | 2025 | 125 | 0.230 |
Why?
|
| Cholera Vaccines | 1 | 2005 | 3 | 0.220 |
Why?
|
| Haplotypes | 1 | 2005 | 134 | 0.220 |
Why?
|
| Cholera | 1 | 2005 | 16 | 0.220 |
Why?
|
| Ticks | 3 | 2021 | 35 | 0.220 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2005 | 179 | 0.220 |
Why?
|
| Administration, Oral | 6 | 2023 | 371 | 0.220 |
Why?
|
| Adult | 29 | 2025 | 17358 | 0.210 |
Why?
|
| Zoonoses | 1 | 2004 | 9 | 0.210 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2004 | 23 | 0.210 |
Why?
|
| Male | 28 | 2025 | 31047 | 0.210 |
Why?
|
| Public Health | 1 | 2006 | 186 | 0.200 |
Why?
|
| Gelatinases | 3 | 1998 | 9 | 0.200 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2003 | 9 | 0.200 |
Why?
|
| Female | 24 | 2025 | 34018 | 0.200 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 114 | 0.190 |
Why?
|
| Salmonella typhimurium | 2 | 2013 | 85 | 0.190 |
Why?
|
| Biomedical Research | 1 | 2006 | 262 | 0.190 |
Why?
|
| Interleukin-2 | 5 | 1998 | 167 | 0.190 |
Why?
|
| Tetanus Toxin | 3 | 1988 | 8 | 0.190 |
Why?
|
| Antibody Specificity | 3 | 2020 | 102 | 0.190 |
Why?
|
| Rabies Vaccines | 1 | 2022 | 4 | 0.180 |
Why?
|
| Babesiosis | 2 | 2006 | 13 | 0.180 |
Why?
|
| Rabies virus | 1 | 2022 | 9 | 0.180 |
Why?
|
| Rabies | 1 | 2022 | 8 | 0.180 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 325 | 0.180 |
Why?
|
| Chemotaxis, Leukocyte | 13 | 1998 | 62 | 0.180 |
Why?
|
| Staphylococcus aureus | 4 | 1988 | 180 | 0.180 |
Why?
|
| Cognition Disorders | 1 | 2003 | 223 | 0.170 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 50 | 0.170 |
Why?
|
| Middle Aged | 15 | 2025 | 18273 | 0.170 |
Why?
|
| Metalloendopeptidases | 2 | 1998 | 20 | 0.170 |
Why?
|
| Influenza, Human | 1 | 2004 | 203 | 0.170 |
Why?
|
| Serology | 1 | 2001 | 1 | 0.170 |
Why?
|
| Kinetics | 12 | 1996 | 760 | 0.170 |
Why?
|
| Autoimmunity | 3 | 1999 | 247 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2016 | 5792 | 0.170 |
Why?
|
| Synovial Fluid | 3 | 2001 | 29 | 0.170 |
Why?
|
| Urinalysis | 1 | 2001 | 37 | 0.170 |
Why?
|
| Mice, SCID | 2 | 2019 | 518 | 0.160 |
Why?
|
| Historiography | 1 | 2000 | 2 | 0.160 |
Why?
|
| Holocaust | 1 | 2000 | 2 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 45 | 0.160 |
Why?
|
| HEK293 Cells | 2 | 2020 | 616 | 0.160 |
Why?
|
| Bacterial Proteins | 5 | 2004 | 742 | 0.160 |
Why?
|
| Escherichia coli Proteins | 2 | 2021 | 277 | 0.160 |
Why?
|
| Phagocytosis | 15 | 1998 | 257 | 0.160 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 7 | 1988 | 18 | 0.150 |
Why?
|
| Plasmids | 3 | 2019 | 294 | 0.150 |
Why?
|
| Young Adult | 2 | 2025 | 4809 | 0.150 |
Why?
|
| Antigens, Bacterial | 4 | 2001 | 202 | 0.150 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 1290 | 0.150 |
Why?
|
| Medicine | 1 | 1999 | 53 | 0.150 |
Why?
|
| Muramidase | 9 | 1998 | 47 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 2293 | 0.140 |
Why?
|
| Genes, Bacterial | 2 | 2001 | 115 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 180 | 0.140 |
Why?
|
| Cytoplasmic Granules | 9 | 1988 | 52 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 805 | 0.130 |
Why?
|
| In Vitro Techniques | 10 | 2015 | 491 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 9 | 2020 | 464 | 0.130 |
Why?
|
| Transfection | 2 | 2019 | 700 | 0.130 |
Why?
|
| Tetradecanoylphorbol Acetate | 5 | 1988 | 62 | 0.130 |
Why?
|
| Cells, Cultured | 8 | 2007 | 2188 | 0.130 |
Why?
|
| Family Practice | 1 | 1999 | 215 | 0.130 |
Why?
|
| Host-Parasite Interactions | 1 | 1997 | 61 | 0.130 |
Why?
|
| Polymers | 1 | 2020 | 332 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2016 | 58 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 1998 | 108 | 0.120 |
Why?
|
| alpha-2-Antiplasmin | 1 | 1996 | 1 | 0.120 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 1996 | 2 | 0.120 |
Why?
|
| Adolescent | 6 | 2025 | 6297 | 0.120 |
Why?
|
| Fibrinolysis | 1 | 1996 | 5 | 0.120 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1996 | 15 | 0.120 |
Why?
|
| Borrelia | 1 | 1996 | 31 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 4 | 1992 | 247 | 0.120 |
Why?
|
| Tick Bites | 1 | 2016 | 11 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1996 | 67 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2016 | 29 | 0.120 |
Why?
|
| Ebolavirus | 1 | 2016 | 39 | 0.110 |
Why?
|
| Nanoparticles | 2 | 2020 | 544 | 0.110 |
Why?
|
| Viral Envelope Proteins | 1 | 2016 | 101 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 460 | 0.110 |
Why?
|
| Aged | 15 | 2015 | 14965 | 0.110 |
Why?
|
| Lymphokines | 3 | 1986 | 67 | 0.110 |
Why?
|
| Receptors, Fc | 1 | 2015 | 25 | 0.110 |
Why?
|
| Autoantibodies | 1 | 2015 | 184 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2020 | 450 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1999 | 767 | 0.100 |
Why?
|
| Neurons | 1 | 1999 | 933 | 0.100 |
Why?
|
| Chemotactic Factors | 3 | 1991 | 25 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2015 | 142 | 0.100 |
Why?
|
| Interleukin-1 | 3 | 1992 | 154 | 0.100 |
Why?
|
| Collagenases | 3 | 1998 | 16 | 0.100 |
Why?
|
| Mycobacterium Infections | 1 | 1993 | 15 | 0.100 |
Why?
|
| Education, Medical | 1 | 1995 | 182 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2013 | 3153 | 0.100 |
Why?
|
| Cross Reactions | 3 | 2020 | 139 | 0.100 |
Why?
|
| Mycobacterium bovis | 1 | 1993 | 29 | 0.100 |
Why?
|
| Leukocyte Migration-Inhibitory Factors | 2 | 1983 | 2 | 0.100 |
Why?
|
| BCG Vaccine | 1 | 1993 | 57 | 0.100 |
Why?
|
| Cell Culture Techniques | 2 | 2007 | 195 | 0.090 |
Why?
|
| Cell Membrane | 10 | 1996 | 506 | 0.090 |
Why?
|
| Mental Disorders | 1 | 2000 | 822 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2003 | 208 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2005 | 730 | 0.090 |
Why?
|
| Homeostasis | 3 | 1988 | 379 | 0.080 |
Why?
|
| Methylamines | 2 | 1988 | 11 | 0.080 |
Why?
|
| Receptors, Immunologic | 3 | 1988 | 179 | 0.080 |
Why?
|
| History, 20th Century | 2 | 2004 | 232 | 0.080 |
Why?
|
| Caco-2 Cells | 2 | 2021 | 67 | 0.080 |
Why?
|
| Ascites | 1 | 2010 | 22 | 0.080 |
Why?
|
| Yersinia pestis | 2 | 1990 | 33 | 0.080 |
Why?
|
| Acute Disease | 2 | 2003 | 663 | 0.080 |
Why?
|
| Shock | 1 | 2010 | 33 | 0.080 |
Why?
|
| Nerve Tissue | 1 | 2010 | 7 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 991 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2010 | 34 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2005 | 1141 | 0.080 |
Why?
|
| Hypotension | 1 | 2010 | 50 | 0.080 |
Why?
|
| Cytosol | 5 | 1988 | 182 | 0.080 |
Why?
|
| Defibrillators, Implantable | 1 | 1993 | 273 | 0.080 |
Why?
|
| Hematoma | 1 | 2010 | 84 | 0.080 |
Why?
|
| Ammonium Chloride | 5 | 1988 | 10 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2010 | 98 | 0.080 |
Why?
|
| Granulomatous Disease, Chronic | 2 | 1991 | 41 | 0.080 |
Why?
|
| Protein Binding | 3 | 2020 | 1640 | 0.080 |
Why?
|
| Music | 1 | 2010 | 75 | 0.080 |
Why?
|
| Oxygen Consumption | 6 | 1988 | 213 | 0.080 |
Why?
|
| Cytochalasin B | 2 | 1987 | 24 | 0.070 |
Why?
|
| Pyrogens | 2 | 1979 | 2 | 0.070 |
Why?
|
| Binding Sites | 5 | 2016 | 921 | 0.070 |
Why?
|
| Leukotriene B4 | 1 | 1988 | 12 | 0.070 |
Why?
|
| Staphylococcal Skin Infections | 1 | 1988 | 12 | 0.070 |
Why?
|
| Chediak-Higashi Syndrome | 1 | 1988 | 3 | 0.070 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1988 | 28 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2010 | 142 | 0.070 |
Why?
|
| Tetanus | 1 | 1988 | 5 | 0.070 |
Why?
|
| Propranolol | 1 | 1988 | 22 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2001 | 856 | 0.070 |
Why?
|
| Alprenolol | 1 | 1988 | 1 | 0.070 |
Why?
|
| Dihydroalprenolol | 1 | 1988 | 1 | 0.070 |
Why?
|
| Propanolamines | 1 | 1988 | 10 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1988 | 34 | 0.070 |
Why?
|
| Azides | 1 | 1988 | 22 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2015 | 611 | 0.070 |
Why?
|
| Phagosomes | 1 | 1988 | 44 | 0.070 |
Why?
|
| Ion Channels | 1 | 1988 | 92 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 1988 | 102 | 0.070 |
Why?
|
| Cell Fractionation | 3 | 1985 | 32 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2001 | 296 | 0.070 |
Why?
|
| Paromomycin | 1 | 2007 | 1 | 0.070 |
Why?
|
| Psychodidae | 1 | 2007 | 1 | 0.070 |
Why?
|
| Antiprotozoal Agents | 1 | 2007 | 8 | 0.070 |
Why?
|
| Leukocytes | 3 | 1991 | 105 | 0.070 |
Why?
|
| U937 Cells | 1 | 2007 | 10 | 0.070 |
Why?
|
| Molecular Weight | 2 | 1997 | 193 | 0.060 |
Why?
|
| Hypersensitivity | 1 | 1988 | 73 | 0.060 |
Why?
|
| Bacterial Adhesion | 2 | 2021 | 65 | 0.060 |
Why?
|
| Vero Cells | 2 | 2020 | 81 | 0.060 |
Why?
|
| Spinal Cord | 1 | 1988 | 209 | 0.060 |
Why?
|
| Anaplasmosis | 1 | 2006 | 4 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 5 | 1998 | 33 | 0.060 |
Why?
|
| Autoantigens | 2 | 2015 | 139 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 1997 | 64 | 0.060 |
Why?
|
| Oxacillin | 2 | 1986 | 4 | 0.060 |
Why?
|
| Tick-Borne Diseases | 1 | 2006 | 8 | 0.060 |
Why?
|
| Operon | 2 | 2004 | 31 | 0.060 |
Why?
|
| Antibody Formation | 2 | 2016 | 110 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 2 | 1998 | 114 | 0.060 |
Why?
|
| Bioterrorism | 1 | 2006 | 8 | 0.060 |
Why?
|
| Rifampin | 1 | 1986 | 24 | 0.060 |
Why?
|
| Oligopeptides | 2 | 2004 | 135 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 26 | 0.060 |
Why?
|
| Vaccines | 1 | 2007 | 96 | 0.060 |
Why?
|
| Vancomycin | 1 | 1986 | 39 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 3 | 1997 | 868 | 0.060 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2005 | 4 | 0.060 |
Why?
|
| HLA-DRB1 Chains | 1 | 2005 | 16 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2003 | 1574 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 1998 | 173 | 0.060 |
Why?
|
| Thiazoles | 1 | 1985 | 45 | 0.060 |
Why?
|
| HLA-DQ Antigens | 1 | 2005 | 14 | 0.060 |
Why?
|
| Disaster Planning | 1 | 2006 | 56 | 0.060 |
Why?
|
| Asia, Southeastern | 1 | 2005 | 9 | 0.060 |
Why?
|
| Water Supply | 1 | 2005 | 16 | 0.060 |
Why?
|
| Digitonin | 1 | 1985 | 4 | 0.060 |
Why?
|
| Boston | 1 | 2006 | 258 | 0.060 |
Why?
|
| Microscopy, Confocal | 2 | 1996 | 240 | 0.060 |
Why?
|
| Daunorubicin | 1 | 1984 | 7 | 0.050 |
Why?
|
| Bacillus | 1 | 2005 | 14 | 0.050 |
Why?
|
| Vibrio cholerae | 1 | 2005 | 18 | 0.050 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2005 | 24 | 0.050 |
Why?
|
| NADP | 1 | 1984 | 21 | 0.050 |
Why?
|
| Complement C6 | 1 | 2004 | 2 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2020 | 1162 | 0.050 |
Why?
|
| Bacteria, Anaerobic | 1 | 1984 | 5 | 0.050 |
Why?
|
| Influenza in Birds | 1 | 2004 | 3 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 513 | 0.050 |
Why?
|
| Poultry | 1 | 2004 | 9 | 0.050 |
Why?
|
| Alleles | 1 | 2005 | 453 | 0.050 |
Why?
|
| Melanoma | 2 | 1998 | 333 | 0.050 |
Why?
|
| Blister | 1 | 2003 | 15 | 0.050 |
Why?
|
| Glucuronidase | 4 | 1998 | 25 | 0.050 |
Why?
|
| Leishmania | 1 | 1983 | 12 | 0.050 |
Why?
|
| Genotype | 1 | 2005 | 673 | 0.050 |
Why?
|
| Sensation Disorders | 1 | 2003 | 23 | 0.050 |
Why?
|
| Complement C5 | 2 | 1980 | 8 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 175 | 0.050 |
Why?
|
| Cell Line | 1 | 2007 | 2024 | 0.050 |
Why?
|
| Influenza A virus | 1 | 2004 | 119 | 0.050 |
Why?
|
| Prognosis | 4 | 2004 | 1784 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2022 | 6 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 542 | 0.050 |
Why?
|
| Affect | 1 | 2003 | 131 | 0.050 |
Why?
|
| CHO Cells | 2 | 2019 | 192 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2005 | 5614 | 0.040 |
Why?
|
| Calcimycin | 3 | 1988 | 19 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2001 | 17 | 0.040 |
Why?
|
| Syndrome | 2 | 2015 | 180 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2021 | 48 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 159 | 0.040 |
Why?
|
| District of Columbia | 1 | 2001 | 9 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 1998 | 29 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 410 | 0.040 |
Why?
|
| Cross Protection | 1 | 2021 | 6 | 0.040 |
Why?
|
| Camelids, New World | 1 | 2021 | 10 | 0.040 |
Why?
|
| Mutation | 3 | 2020 | 2661 | 0.040 |
Why?
|
| Fimbriae Proteins | 1 | 2021 | 13 | 0.040 |
Why?
|
| Gastric Acid | 1 | 2021 | 9 | 0.040 |
Why?
|
| Antibody Affinity | 1 | 2021 | 18 | 0.040 |
Why?
|
| Dogs | 1 | 2022 | 315 | 0.040 |
Why?
|
| Epitope Mapping | 1 | 2021 | 52 | 0.040 |
Why?
|
| Plants, Genetically Modified | 1 | 2021 | 23 | 0.040 |
Why?
|
| Silicon | 1 | 2020 | 17 | 0.040 |
Why?
|
| Porosity | 1 | 2020 | 41 | 0.040 |
Why?
|
| Gelatin | 1 | 2020 | 29 | 0.040 |
Why?
|
| Recombinant Proteins | 4 | 1998 | 710 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 2020 | 51 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 238 | 0.040 |
Why?
|
| Pain | 1 | 2003 | 399 | 0.040 |
Why?
|
| Glycosylation | 1 | 2021 | 138 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2021 | 95 | 0.040 |
Why?
|
| Fluorescent Dyes | 2 | 1995 | 202 | 0.040 |
Why?
|
| Solubility | 1 | 2020 | 192 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2021 | 190 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 86 | 0.040 |
Why?
|
| Hydrogen Peroxide | 4 | 1988 | 83 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2021 | 260 | 0.040 |
Why?
|
| Aotidae | 1 | 2020 | 11 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2020 | 82 | 0.040 |
Why?
|
| Blood Bactericidal Activity | 3 | 1990 | 61 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2015 | 185 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2001 | 135 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2001 | 1589 | 0.040 |
Why?
|
| Phosphates | 1 | 2020 | 104 | 0.040 |
Why?
|
| Drug Design | 1 | 2021 | 137 | 0.040 |
Why?
|
| Tuftsin | 1 | 1979 | 1 | 0.040 |
Why?
|
| gamma-Globulins | 1 | 1979 | 10 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 1999 | 31 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2020 | 181 | 0.040 |
Why?
|
| Antigen-Antibody Complex | 2 | 2016 | 52 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2004 | 1559 | 0.040 |
Why?
|
| Cricetulus | 1 | 2019 | 103 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2004 | 718 | 0.040 |
Why?
|
| Drug Stability | 1 | 2019 | 144 | 0.040 |
Why?
|
| Opsonin Proteins | 3 | 1984 | 32 | 0.040 |
Why?
|
| Receptors, Formyl Peptide | 3 | 1988 | 6 | 0.040 |
Why?
|
| Cloning, Molecular | 2 | 1997 | 385 | 0.040 |
Why?
|
| Astrocytes | 1 | 1999 | 123 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2019 | 79 | 0.040 |
Why?
|
| Interleukin-11 | 1 | 1998 | 8 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 1980 | 191 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 2 | 2013 | 47 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 187 | 0.040 |
Why?
|
| Biomarkers | 1 | 2004 | 1480 | 0.040 |
Why?
|
| Membrane Proteins | 4 | 1995 | 919 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2021 | 274 | 0.030 |
Why?
|
| Clinical Enzyme Tests | 1 | 1998 | 13 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1998 | 13 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1998 | 80 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1978 | 48 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1998 | 64 | 0.030 |
Why?
|
| Mice, Inbred AKR | 1 | 1997 | 12 | 0.030 |
Why?
|
| Cell Separation | 1 | 1978 | 147 | 0.030 |
Why?
|
| Central Nervous System | 1 | 1999 | 200 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 1997 | 84 | 0.030 |
Why?
|
| Ionomycin | 2 | 1988 | 16 | 0.030 |
Why?
|
| Ethers | 2 | 1988 | 17 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 1998 | 62 | 0.030 |
Why?
|
| Cell Adhesion | 5 | 1986 | 218 | 0.030 |
Why?
|
| Th2 Cells | 1 | 1997 | 93 | 0.030 |
Why?
|
| Aminoquinolines | 2 | 1988 | 16 | 0.030 |
Why?
|
| Temperature | 3 | 1983 | 316 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 1998 | 102 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1978 | 192 | 0.030 |
Why?
|
| Erythrocytes | 3 | 1984 | 146 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1997 | 300 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1990 | 604 | 0.030 |
Why?
|
| Structural Homology, Protein | 1 | 2016 | 22 | 0.030 |
Why?
|
| Th1 Cells | 1 | 1997 | 171 | 0.030 |
Why?
|
| Cytokines | 2 | 1998 | 952 | 0.030 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 1996 | 6 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1997 | 1979 | 0.030 |
Why?
|
| Pancreatic Elastase | 1 | 1996 | 32 | 0.030 |
Why?
|
| Quinine | 1 | 1996 | 3 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 1996 | 4 | 0.030 |
Why?
|
| Hot Temperature | 2 | 1988 | 145 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2016 | 156 | 0.030 |
Why?
|
| Depression | 1 | 2003 | 900 | 0.030 |
Why?
|
| Ebola Vaccines | 1 | 2016 | 2 | 0.030 |
Why?
|
| Spectrophotometry | 1 | 1996 | 30 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2001 | 1698 | 0.030 |
Why?
|
| Democratic Republic of the Congo | 1 | 2016 | 19 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 1997 | 3485 | 0.030 |
Why?
|
| Parasitemia | 1 | 1996 | 49 | 0.030 |
Why?
|
| Azithromycin | 1 | 1996 | 34 | 0.030 |
Why?
|
| Rats | 1 | 1999 | 1994 | 0.030 |
Why?
|
| Recurrence | 3 | 2004 | 657 | 0.030 |
Why?
|
| Chloroquine | 2 | 1986 | 56 | 0.030 |
Why?
|
| Antigens, CD | 1 | 1997 | 342 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2016 | 419 | 0.030 |
Why?
|
| Exocytosis | 2 | 1987 | 61 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2016 | 145 | 0.030 |
Why?
|
| Fibrinolysin | 1 | 1995 | 6 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 39 | 0.030 |
Why?
|
| Virion | 1 | 2016 | 122 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1997 | 500 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 1998 | 347 | 0.030 |
Why?
|
| Antimalarials | 1 | 1996 | 126 | 0.030 |
Why?
|
| Endopeptidases | 1 | 1995 | 67 | 0.030 |
Why?
|
| Massachusetts | 1 | 2001 | 2145 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 1999 | 1008 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 81 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 1998 | 318 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 186 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1995 | 129 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 1997 | 563 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2005 | 1163 | 0.030 |
Why?
|
| Forecasting | 1 | 1995 | 230 | 0.030 |
Why?
|
| Child | 2 | 2023 | 4607 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1999 | 706 | 0.030 |
Why?
|
| Quality of Life | 1 | 2001 | 1260 | 0.030 |
Why?
|
| Binding, Competitive | 2 | 2004 | 96 | 0.030 |
Why?
|
| Phagocytes | 2 | 1986 | 52 | 0.030 |
Why?
|
| Helminthiasis | 1 | 2013 | 7 | 0.030 |
Why?
|
| Time Factors | 3 | 1986 | 3762 | 0.030 |
Why?
|
| Rabbits | 4 | 1990 | 338 | 0.020 |
Why?
|
| Administration, Intravesical | 1 | 1993 | 14 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1997 | 641 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1993 | 111 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 1998 | 643 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1993 | 45 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 233 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 896 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 63 | 0.020 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 2 | 1982 | 5 | 0.020 |
Why?
|
| Gramicidin | 2 | 1982 | 6 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 1992 | 49 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1992 | 72 | 0.020 |
Why?
|
| Culture Media | 1 | 1992 | 78 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 1997 | 408 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1993 | 108 | 0.020 |
Why?
|
| Virulence | 3 | 1990 | 199 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 426 | 0.020 |
Why?
|
| Interleukin-8 | 2 | 1998 | 96 | 0.020 |
Why?
|
| Serial Passage | 1 | 1991 | 3 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 1991 | 62 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 1991 | 47 | 0.020 |
Why?
|
| Cell Movement | 3 | 1983 | 482 | 0.020 |
Why?
|
| Cell Survival | 1 | 1992 | 587 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1992 | 220 | 0.020 |
Why?
|
| Plague | 1 | 1990 | 23 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1992 | 261 | 0.020 |
Why?
|
| Rosette Formation | 2 | 1980 | 12 | 0.020 |
Why?
|
| Dexamethasone | 1 | 1990 | 213 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1980 | 101 | 0.020 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 1989 | 20 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1992 | 364 | 0.020 |
Why?
|
| Receptors, Leukotriene B4 | 1 | 1988 | 2 | 0.020 |
Why?
|
| Ionophores | 1 | 1988 | 11 | 0.020 |
Why?
|
| Vanadates | 1 | 1988 | 7 | 0.020 |
Why?
|
| Prostaglandins D | 1 | 1988 | 1 | 0.020 |
Why?
|
| Prostaglandins E | 1 | 1988 | 8 | 0.020 |
Why?
|
| Hypersensitivity, Immediate | 1 | 1988 | 6 | 0.020 |
Why?
|
| Monensin | 1 | 1988 | 4 | 0.020 |
Why?
|
| Immunosorbent Techniques | 1 | 1988 | 9 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 1988 | 46 | 0.020 |
Why?
|
| Random Allocation | 1 | 1988 | 200 | 0.020 |
Why?
|
| Affinity Labels | 1 | 1988 | 10 | 0.020 |
Why?
|
| Histamine | 1 | 1988 | 21 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1988 | 65 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 6 | 0.020 |
Why?
|
| Drug Synergism | 2 | 1986 | 142 | 0.020 |
Why?
|
| Biological Transport | 1 | 1988 | 292 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 428 | 0.020 |
Why?
|
| Intracellular Fluid | 1 | 1987 | 32 | 0.020 |
Why?
|
| Immunophenotyping | 2 | 1998 | 194 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1988 | 153 | 0.020 |
Why?
|
| Receptors, Complement | 1 | 1986 | 15 | 0.020 |
Why?
|
| Ehrlichiosis | 1 | 2006 | 6 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 1988 | 301 | 0.020 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 1986 | 34 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2013 | 706 | 0.020 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 1986 | 18 | 0.010 |
Why?
|
| Chemotaxis | 2 | 1990 | 51 | 0.010 |
Why?
|
| Hexosaminidases | 1 | 1985 | 6 | 0.010 |
Why?
|
| Lymphocytes | 2 | 1984 | 209 | 0.010 |
Why?
|
| Neoplasms | 1 | 1996 | 1368 | 0.010 |
Why?
|
| NADPH Oxidases | 1 | 1986 | 69 | 0.010 |
Why?
|
| Substrate Specificity | 2 | 2004 | 341 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1986 | 166 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1985 | 84 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 1220 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1986 | 206 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 485 | 0.010 |
Why?
|
| Silicon Dioxide | 1 | 2005 | 63 | 0.010 |
Why?
|
| Propionibacterium | 1 | 1984 | 5 | 0.010 |
Why?
|
| Bacteroides | 1 | 1984 | 10 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1984 | 20 | 0.010 |
Why?
|
| Adenylyl Cyclases | 1 | 1984 | 21 | 0.010 |
Why?
|
| Pseudomonas Infections | 1 | 1984 | 73 | 0.010 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2004 | 8 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 170 | 0.010 |
Why?
|
| Subcellular Fractions | 2 | 1981 | 67 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2004 | 52 | 0.010 |
Why?
|
| C-Reactive Protein | 2 | 1998 | 170 | 0.010 |
Why?
|
| Surface Properties | 1 | 2005 | 283 | 0.010 |
Why?
|
| Peptide Library | 1 | 2004 | 33 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 327 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1984 | 54 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1985 | 417 | 0.010 |
Why?
|
| Erythrocyte Membrane | 1 | 1983 | 25 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 413 | 0.010 |
Why?
|
| Blood Proteins | 2 | 1981 | 84 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1983 | 94 | 0.010 |
Why?
|
| Valinomycin | 1 | 1982 | 3 | 0.010 |
Why?
|
| Particle Size | 1 | 2005 | 428 | 0.010 |
Why?
|
| Tritium | 1 | 1982 | 22 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2004 | 146 | 0.010 |
Why?
|
| Gold | 1 | 2005 | 235 | 0.010 |
Why?
|
| Acetylglucosamine | 1 | 1982 | 11 | 0.010 |
Why?
|
| Absorption | 1 | 1982 | 11 | 0.010 |
Why?
|
| Health Personnel | 1 | 2006 | 384 | 0.010 |
Why?
|
| Bacteroides fragilis | 1 | 1982 | 5 | 0.010 |
Why?
|
| Phospholipases | 1 | 1981 | 9 | 0.010 |
Why?
|
| Phospholipases A | 1 | 1981 | 15 | 0.010 |
Why?
|
| Cathepsins | 1 | 1982 | 34 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1982 | 44 | 0.010 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2001 | 4 | 0.010 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2001 | 7 | 0.010 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2001 | 9 | 0.010 |
Why?
|
| Synovial Membrane | 1 | 2001 | 21 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 1113 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2001 | 45 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 2001 | 38 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 2001 | 67 | 0.010 |
Why?
|
| Meningitis | 2 | 1998 | 18 | 0.010 |
Why?
|
| Centrifugation | 1 | 1980 | 10 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1980 | 21 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1980 | 254 | 0.010 |
Why?
|
| Nitroblue Tetrazolium | 1 | 1979 | 8 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1979 | 18 | 0.010 |
Why?
|
| Neutropenia | 1 | 1980 | 68 | 0.010 |
Why?
|
| Cytochrome c Group | 2 | 1991 | 25 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2001 | 312 | 0.010 |
Why?
|
| Brain | 1 | 1988 | 1605 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1986 | 1630 | 0.010 |
Why?
|
| Penicillin Resistance | 1 | 1979 | 11 | 0.010 |
Why?
|
| Streptococcus | 1 | 1979 | 19 | 0.010 |
Why?
|
| Penicillins | 1 | 1979 | 32 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1980 | 189 | 0.010 |
Why?
|
| Endocarditis, Bacterial | 1 | 1979 | 36 | 0.010 |
Why?
|
| Dinoprostone | 2 | 1989 | 41 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1998 | 22 | 0.010 |
Why?
|
| Naproxen | 1 | 1978 | 6 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1979 | 84 | 0.010 |
Why?
|
| Regional Medical Programs | 1 | 1998 | 8 | 0.010 |
Why?
|
| Cations, Divalent | 1 | 1978 | 25 | 0.010 |
Why?
|
| Nitrates | 1 | 1998 | 21 | 0.010 |
Why?
|
| Clinical Medicine | 1 | 1998 | 16 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1978 | 35 | 0.010 |
Why?
|
| Indomethacin | 1 | 1978 | 23 | 0.010 |
Why?
|
| Lactoferrin | 1 | 1978 | 37 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1998 | 95 | 0.010 |
Why?
|
| Career Mobility | 1 | 1998 | 62 | 0.010 |
Why?
|
| Research Personnel | 1 | 1998 | 82 | 0.010 |
Why?
|
| Cricetinae | 1 | 1998 | 362 | 0.010 |
Why?
|
| Genetic Linkage | 2 | 1991 | 97 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 1997 | 29 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1996 | 54 | 0.010 |
Why?
|
| Etanercept | 1 | 1996 | 33 | 0.010 |
Why?
|
| Program Evaluation | 1 | 1998 | 493 | 0.010 |
Why?
|
| Societies, Medical | 1 | 1998 | 399 | 0.010 |
Why?
|
| Neurocognitive Disorders | 1 | 1975 | 7 | 0.010 |
Why?
|
| Prednisone | 1 | 1975 | 83 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 1975 | 57 | 0.010 |
Why?
|
| Curriculum | 1 | 1998 | 608 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1975 | 183 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1992 | 15 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1992 | 40 | 0.010 |
Why?
|
| X Chromosome | 1 | 1991 | 52 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1990 | 19 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1991 | 170 | 0.010 |
Why?
|
| Base Sequence | 1 | 1991 | 1332 | 0.000 |
Why?
|
| DNA Transposable Elements | 1 | 1990 | 160 | 0.000 |
Why?
|
| Fish Oils | 1 | 1989 | 43 | 0.000 |
Why?
|
| Prostaglandin D2 | 1 | 1988 | 3 | 0.000 |
Why?
|
| RNA | 1 | 1991 | 426 | 0.000 |
Why?
|
| Age Factors | 1 | 1991 | 1586 | 0.000 |
Why?
|
| Gene Expression | 1 | 1990 | 852 | 0.000 |
Why?
|
| Receptors, Complement 3b | 1 | 1986 | 12 | 0.000 |
Why?
|
| DNA | 1 | 1991 | 858 | 0.000 |
Why?
|
| Radioligand Assay | 1 | 1986 | 24 | 0.000 |
Why?
|
| Phenotype | 1 | 1990 | 1233 | 0.000 |
Why?
|
| Granulocytes | 1 | 1986 | 73 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1990 | 1386 | 0.000 |
Why?
|
| Uncoupling Agents | 1 | 1984 | 5 | 0.000 |
Why?
|
| Enzyme Activation | 1 | 1984 | 391 | 0.000 |
Why?
|
| Cathepsin G | 1 | 1982 | 1 | 0.000 |
Why?
|
| Bacteroides Infections | 1 | 1982 | 5 | 0.000 |
Why?
|
| Phospholipases A2 | 1 | 1981 | 15 | 0.000 |
Why?
|
| Ferritins | 1 | 1982 | 30 | 0.000 |
Why?
|
| Permeability | 1 | 1981 | 50 | 0.000 |
Why?
|
| Angiotensin II | 1 | 1982 | 25 | 0.000 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 1981 | 73 | 0.000 |
Why?
|
| Serine Endopeptidases | 1 | 1982 | 121 | 0.000 |
Why?
|
| Endoplasmic Reticulum | 1 | 1981 | 177 | 0.000 |
Why?
|
| Immune Adherence Reaction | 1 | 1980 | 1 | 0.000 |
Why?
|
| Sex Chromosomes | 1 | 1980 | 12 | 0.000 |
Why?
|
| Kartagener Syndrome | 1 | 1980 | 7 | 0.000 |
Why?
|
| Immunoglobulin E | 1 | 1980 | 81 | 0.000 |
Why?
|
| Burns | 1 | 1980 | 45 | 0.000 |
Why?
|
| Penicillin G | 1 | 1979 | 5 | 0.000 |
Why?
|
| Streptomycin | 1 | 1979 | 14 | 0.000 |
Why?
|
| Rheumatic Fever | 1 | 1979 | 5 | 0.000 |
Why?
|
| Gentamicins | 1 | 1979 | 24 | 0.000 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1975 | 5 | 0.000 |
Why?
|
| Azathioprine | 1 | 1975 | 27 | 0.000 |
Why?
|
| Psychotropic Drugs | 1 | 1975 | 81 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1980 | 2061 | 0.000 |
Why?
|